216 related articles for article (PubMed ID: 24232489)
1. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab.
Avery RA; Hwang EI; Jakacki RI; Packer RJ
JAMA Ophthalmol; 2014 Jan; 132(1):111-4. PubMed ID: 24232489
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas.
Kelly JP; Leary S; Khanna P; Weiss AH
Ophthalmology; 2012 Jun; 119(6):1231-7. PubMed ID: 22364864
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review.
Yamasaki F; Takano M; Yonezawa U; Taguchi A; Kolakshyapati M; Okumichi H; Kiuchi Y; Kurisu K
Childs Nerv Syst; 2020 Mar; 36(3):635-639. PubMed ID: 31701281
[TBL] [Abstract][Full Text] [Related]
4. Handheld optical coherence tomography during sedation in young children with optic pathway gliomas.
Avery RA; Hwang EI; Ishikawa H; Acosta MT; Hutcheson KA; Santos D; Zand DJ; Kilburn LB; Rosenbaum KN; Rood BR; Schuman JS; Packer RJ
JAMA Ophthalmol; 2014 Mar; 132(3):265-71. PubMed ID: 24435762
[TBL] [Abstract][Full Text] [Related]
5. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.
Ullrich NJ; Prabhu SP; Packer RJ; Goldman S; Robison NJ; Allen JC; Viskochil DH; Gutmann DH; Perentesis JP; Korf BR; Fisher MJ; Kieran MW;
Pediatr Blood Cancer; 2021 Apr; 68(4):e28833. PubMed ID: 33336845
[TBL] [Abstract][Full Text] [Related]
6. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More.
Kinori M; Armarnik S; Listernick R; Charrow J; Zeid JL
Am J Ophthalmol; 2021 Jan; 221():91-96. PubMed ID: 32283094
[TBL] [Abstract][Full Text] [Related]
7. Visual acuity of children treated with chemotherapy for optic pathway gliomas.
Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH
Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233
[TBL] [Abstract][Full Text] [Related]
8. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.
Falzon K; Drimtzias E; Picton S; Simmons I
Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527
[TBL] [Abstract][Full Text] [Related]
9. Visual improvement despite radiologically stable disease after treatment with carboplatin in children with progressive low-grade optic/thalamic gliomas.
Mitchell AE; Elder JE; Mackey DA; Waters KD; Ashley DM
J Pediatr Hematol Oncol; 2001 Dec; 23(9):572-7. PubMed ID: 11902299
[TBL] [Abstract][Full Text] [Related]
10. Visual outcome following chemotherapy for progressive optic pathway gliomas.
Shofty B; Ben-Sira L; Freedman S; Yalon M; Dvir R; Weintraub M; Toledano H; Constantini S; Kesler A
Pediatr Blood Cancer; 2011 Sep; 57(3):481-5. PubMed ID: 21241008
[TBL] [Abstract][Full Text] [Related]
11. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT
Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213
[TBL] [Abstract][Full Text] [Related]
12. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.
Avery RA; Bouffet E; Packer RJ; Reginald A
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1034-8. PubMed ID: 23329671
[TBL] [Abstract][Full Text] [Related]
14. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program.
Dalla Via P; Opocher E; Pinello ML; Calderone M; Viscardi E; Clementi M; Battistella PA; Laverda AM; Da Dalt L; Perilongo G
Neuro Oncol; 2007 Oct; 9(4):430-7. PubMed ID: 17704361
[TBL] [Abstract][Full Text] [Related]
15. Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1.
Campagna M; Opocher E; Viscardi E; Calderone M; Severino SM; Cermakova I; Perilongo G
Pediatr Blood Cancer; 2010 Dec; 55(6):1083-8. PubMed ID: 20979170
[TBL] [Abstract][Full Text] [Related]
16. Vision specific quality of life in children with optic pathway gliomas.
Avery RA; Hardy KK
J Neurooncol; 2014 Jan; 116(2):341-7. PubMed ID: 24197987
[TBL] [Abstract][Full Text] [Related]
17. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
18. Choroidal neovascularization of optic disk melanocytoma treated with bevacizumab.
Kamisasanuk T; Uchino E; Sakamoto T
Eur J Ophthalmol; 2012; 22(3):503-5. PubMed ID: 21959681
[TBL] [Abstract][Full Text] [Related]
19. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1.
Wan MJ; Ullrich NJ; Manley PE; Kieran MW; Goumnerova LC; Heidary G
J Neurooncol; 2016 Aug; 129(1):173-8. PubMed ID: 27311725
[TBL] [Abstract][Full Text] [Related]
20. Retinal nerve fiber layer thickness in children with optic pathway gliomas.
Avery RA; Liu GT; Fisher MJ; Quinn GE; Belasco JB; Phillips PC; Maguire MG; Balcer LJ
Am J Ophthalmol; 2011 Mar; 151(3):542-9.e2. PubMed ID: 21232732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
